TNFA - Rasio utang marang kapitalisasi buku tnfpharma.com

Risks for TNF Pharmaceuticals (TNFA) are linked to the search for treatments for autoimmune pathologies and aging via funds. Monitoring of borrowed funds relative to balance sheet capital confirms stability, where the 0.00 metric reflects current dynamics. Stability is bolstered by alliances with laboratories focused on combating inflammation, which enhance investment attractiveness, as well as a compact, dedicated research staff that prevents the loss of key expertise.

TNFA (TNF Pharmaceuticals, Inc.) riwayat Utang marang nilai buku saka 25.07.2024 nganti 25.09.2025

tnfpharma.com (TNFA) - rincian metrik lan laporan keuangan

- rega lan prakiraan konsensus rega:
Rega saham TNF Pharmaceuticals, Inc.|TNFA - Prakiraan konsensus analis
- data kapitalisasi pasar:
Nilai pasar TNF Pharmaceuticals, Inc.|TNFA - Nilai Dipunlarasaken Utang lan Kas
- data kapitalisasi buku:
Aset Bersih saben Siji Saham TNF Pharmaceuticals|TNFA - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku tnfpharma.com|TNFA - Total Aset Perusahaan
- data utang lan likuiditas:
Rasio Total Utang marang Ekuitas TNF Pharmaceuticals|TNFA - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas TNF Pharmaceuticals, Inc.|TNFA - Utang kumulatif perusahaan|Utang marang nilai buku TNF Pharmaceuticals, Inc.
Analisis kabeh metrik perusahaan:TNFA TNF Pharma

The stability of TNF Pharmaceuticals (TNFA) relies on its potential for pricing power within the immunology segment. The debt-to-book capitalization ratio illustrates the relationship between the company's borrowed funds and its equity. A decrease in this metric indicates financial stability, whereas an increase suggests aggressive leverage. For a developer of unique therapies, the balance of borrowings is critical when funding R&D. This indicator allows for a determination of whether the market value is fair relative to the debt load.

Pesaing TNF Pharmaceuticals

Utang-utang marang kapitalisasi buku HLN (Haleon plc)|kenvue.com - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Verona Pharma (VRNA)|MENS: Rasio utang marang aset resik|LGND (Ligand Pharma) - Rasio utang marang kapitalisasi buku|Amneal Corp (AMRX) - Utang marang nilai buku|PRGO (Perrigo Company plc) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku alvotech.com (ALVO)|Liquidia (LQDA) - Utang marang nilai buku|Rasio utang marang aset resik GLPG (Galapagos N.V.)|ANIP: Rasio utang marang kapitalisasi buku|MNKD - Utang-utang marang nilai buku|Utang marang nilai buku Amphastar Pharmaceuticals AMPH|PCRX - Utang marang modal buku|Utang-utang marang kapitalisasi buku ARS Pharmaceuticals, Inc. SPRY|Theravance Biopharma Inc (TBPH) - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku AQST (Aquestive Pharma)|Utang-utang marang nilai buku SCPH|Tectonic Therapeutic, Inc. (TECX) - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik tonixpharma.com TNXP|Utang marang nilai buku China SXT Pharmaceuticals, Inc. (SXTC)|Eupraxia Pharmaceuticals, Inc. - Utang marang modal buku|BioHarvest (BHST) - Rasio utang marang kapitalisasi buku|EXOZ - Rasio utang marang nilai buku|Utang-utang marang kapitalisasi buku oramed.com (ORMP)|Rasio utang-utang marang kapitalisasi buku Entera Bio|HYFT - Utang marang nilai buku|Rasio utang marang aset resik ABVC|CPIX - Rasio utang marang kapitalisasi buku|Rasio utang-utang marang kapitalisasi buku Quantum BioPharma Corp (QNTM)|Utang-utang marang kapitalisasi buku FibroGen, Inc.|Rasio utang marang aset resik telomirpharma.com TELO|Rani Therapeutics Inc - Utang-utang marang kapitalisasi buku|SNYR: Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku rallybio.com RLYB|LEXX (Lexaria Bioscience Corp.) - Rasio utang marang aset resik|Rasio utang marang kapitalisasi buku PULM|Utang marang nilai buku Pheton|Utang-utang marang kapitalisasi buku APM|Utang-utang marang kapitalisasi buku Lyra Therapeutics Inc. (LYRA)|Impact BioMedical Inc - Utang-utang marang kapitalisasi buku|Utang marang nilai buku cbdMD Inc. YCBD|PRFX (PainReform Ltd.) - Utang-utang marang kapitalisasi buku|Altamira Therapeutics (CYTO) - Utang-utang marang nilai buku|LIPO: Utang marang nilai buku|Utang-utang marang kapitalisasi buku OptiNose Inc|Pieris (PIRS) - Utang marang nilai buku|Utang marang modal buku Procaps Group Corp|PTPI (Petros Pharmaceuticals) - Utang-utang marang kapitalisasi buku|Utang-utang marang aset resik qlsyy.net (QLI)|ACELYRIN - Utang-utang marang kapitalisasi buku|Utang marang nilai buku TFF Pharmaceuticals Inc. TFFP